Figure 1 from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma

Antitumor effects of amivantamab w/wo pembrolizumab in HNSCC and LUSC tumor–bearing humanized PDX preclinical models. A, The intensity of EGFR and MET in YHIM-3003 (HNSCC) and YHIM-2010 (LUSC) tumors. B, The tumor progression of YHIM-3003 model over 19 days showing significant tumor regression by the combination treatment of amivantamab (30 mpk) and pembrolizumab (10 mpk) compared to single treatment of amivantamab and pembrolizumab (P n = 10 in each group). C, Tumor growth inhibition represented in a waterfall plot of HNSCC PDX model at day 19. D, Survival curve of HNSCC PDX demonstrating improved survival by the combination treatment (n = 10 in each group). E, Treatment of LUSC PDX using amivantamab at 30 mpk in combination with pembrolizumab (10 mpk, n = 10 in each group). No rebound of tumor growth was observed after the termination of amivantamab and combination treatment. F, Tumor regression in LUSC PDX showing significant tumor reduction by combination treatment of amivantamab (10 mpk) and pembrolizumab (10 mpk) compared to single treatment of amivantamab (P P n = 10 in each group). G, Survival curve of LUSC PDX demonstrating improved survival by the combination treatment.